Compare ACADIA Pharmaceuticals Inc. (ACAD) vs FuelCell Energy Inc (FCEL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs FuelCell Energy Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.82 (market cap $4.49B), while FuelCell Energy Inc trades at $22.95 (market cap $1.76B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 2.6× FuelCell Energy Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, FuelCell Energy Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | FCEL | |
|---|---|---|
Market Cap | $4.49B | $1.76B |
Sector | Health | Industrials |
52-Week High | $28.06 | $36.01 |
52-Week Low | $20.06 | $3.92 |
Enterprise Value | $3.69B | $1.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
FCEL trades at $25.96, down 7.65% amid a $200 million stock offering announcement, yet maintains a bullish technical signal with support near $25. Revenue grew to $158.16M in 2025, but profitability remains challenged with a net income margin of -132.41%. Recent news highlights a 5 GW proposal pipeline, with 90% tied to data center power demand, and a $49 million EXIM financing boost for global expansion.
The outlook is speculative; growth potential from AI-driven data center deals and clean energy exports is offset by persistent losses, negative cash flow from operations, and dilution risk from equity offerings. Analyst consensus is mixed with a $20.13 price target, suggesting caution despite bullish technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →
